化合物 CC-401 Hydrochloride|T5833|TargetMol

CC-401 Hydrochloride
1438391-30-0

￥315 1mg 起订

￥745 5mg 起订

￥1160 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 CC-401 Hydrochloride

英文名称：: CC-401 Hydrochloride

CAS号：: 1438391-30-0

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: ≥95%

产品类别：: 抑制剂

货号：: T5833

Product Introduction

Bioactivity

名称	CC-401 Hydrochloride
描述	CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor (Ki of 25 to 50 nM.)with potential antineoplastic activity.
动物实验	To assess the efficacy of JNK signaling inhibition by CC-401 in anti-angiogenic and oxaliplatin combination therapy in a mouse xenograft model, adult (8-10 weeks of age) female severe combined immunodeficient mice (C.B.17 SCID) were used.?To generate tumors, HT29 cells (1 × 10^6 cells) were injected subcutaneously into the left flank of the mice.?When the tumors reached approximately 200 mm^3, mice were divided into eight groups (eight mice per group) for treatment with bevacizumab , oxaliplatin, CC401, and the appropriate combinations of bevacizumab, oxaliplatin and CC-401.?Mice in the bevacizumab treatment group received 5 mg/kg of bevacizumab by intraperitoneal injection every 3 days for 21 days.?The oxaliplatin treatment group was injected intraperitoneally with 5 mg/kg oxaliplatin per week for 2 weeks.?The CC-401 treatment group was injected intraperitoneally 25 mg/kg for every 3 days.?The combination treatment groups received bevacizumab (every 3 days, 5 mg/kg), oxaliplatin (weekly for 2 weeks, 5 mg/kg), and CC-401 (every 3 days, 25 mg/kg).?The control group received saline intraperitoneally.?Tumor volume and body weight were measured every 3 days.?Tumor volume was calculated using the formula V = AB^2/2, where A is the largest diameter and B is the smallest diameter.?Tumor growth delay was calculated as the difference in the time for control and treated tumors to grow from 200 to 800 mm^3.?For tumor growth delay calculations, mice were continued to receive treatments till the tumor volume reached 800 mm^3.?For immunohistochemistry mice were sacrificed after treatments on day 9 for tumor processing and staining.
体外活性	CC-401与化疗化合物联合在结肠癌细胞系中展现出协同作用，尽管这种协同作用并非总是特异性与低氧有关。详细分析主要针对HT29和SW620（敏感）及HCT116（不敏感）细胞系。在HT29和SW620细胞中，CC-401治疗导致敏感细胞中的DNA损伤更为显著。
体内活性	在体内，通过JNK抑制增强了bevacizumab、oxaliplatin及其联合使用在HT29衍生的小鼠异种移植瘤中的效果，其中CC-401存在时的肿瘤生长延迟更为显著。最终，将一个占优势的负向JNK1构建（但不是JNK2）稳定引入HT29细胞中，使其在低氧条件下对oxaliplatin的敏感度提高，这表明JNK亚型在细胞对化疗反应中有不同的输入。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 100 mg/mL (235.33 mM)
关键字	CC 401 Hydrochloride \| CC-401 \| Inhibitor \| JNK \| CC401 Hydrochloride \| CC 401 \| CC401 \| inhibit \| CC-401 Hydrochloride
相关产品	Astragaloside IV \| Bentamapimod \| (-)-Bornyl acetate \| Anisomycin \| TCS JNK 5a \| JNK-IN-13 \| (E)-Ferulic acid methyl ester \| Urolithin B \| SP600125 \| SR-3306 \| Ginsenoside Re \| SKLB-163
相关库	经典已知活性库 \| 抗癌活性化合物库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 抗衰老化合物库 \| 神经退行性疾病化合物库 \| 药物功能重定位化合物库 \| 疼痛相关化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

CC401 HCl|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务